ZA200409388B - Methods and compositions using immunodulatory compounds for treatment and management of cancers and other diseases - Google Patents

Methods and compositions using immunodulatory compounds for treatment and management of cancers and other diseases

Info

Publication number: ZA200409388B
Authority: ZA; South Africa
Prior art keywords: methods; diseases; immunodulatory; cancers; compositions
Prior art date: 2002-05-17

Application number

ZA200409388A

Other languages

English (en)

Inventor

Jerome B Zeldis

Original Assignee

Celgene Corp

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2002-05-17

Filing date

2004-11-22

Publication date

2006-05-31

Family has litigation

First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=29553516&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ZA200409388(B) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.

2004-11-22 Application filed by Celgene Corp filed Critical Celgene Corp

2006-05-31 Publication of ZA200409388B publication Critical patent/ZA200409388B/xx

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
- A61K31/4035—Isoindoles, e.g. phthalimide
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/425—Thiazoles
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
- A61K31/454—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/513—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim having oxo groups directly attached to the heterocyclic ring, e.g. cytosine
- A61K31/515—Barbituric acids; Derivatives thereof, e.g. sodium pentobarbital
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/16—Central respiratory analeptics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/10—Anti-acne agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/12—Keratolytics, e.g. wart or anti-corn preparations
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
- A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A61P25/32—Alcohol-abuse
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A61P27/06—Antiglaucoma agents or miotics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A61P27/10—Ophthalmic agents for accommodation disorders, e.g. myopia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A61P27/14—Decongestants or antiallergics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
- A61P31/08—Antibacterial agents for leprosy
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/10—Antimycotics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/20—Antivirals for DNA viruses
- A61P31/22—Antivirals for DNA viruses for herpes viruses
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P33/00—Antiparasitic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P33/00—Antiparasitic agents
- A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P33/00—Antiparasitic agents
- A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
- A61P33/06—Antimalarials
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P41/00—Drugs used in surgical methods, e.g. surgery adjuvants for preventing adhesion or for vitreum substitution
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/06—Antianaemics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/14—Vasoprotectives; Antihaemorrhoidals; Drugs for varicose therapy; Capillary stabilisers
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

Health & Medical Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Veterinary Medicine (AREA)
Pharmacology & Pharmacy (AREA)
Chemical & Material Sciences (AREA)
Public Health (AREA)
General Health & Medical Sciences (AREA)
Medicinal Chemistry (AREA)
Animal Behavior & Ethology (AREA)
General Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Chemical Kinetics & Catalysis (AREA)
Engineering & Computer Science (AREA)
Bioinformatics & Cheminformatics (AREA)
Epidemiology (AREA)
Oncology (AREA)
Immunology (AREA)
Communicable Diseases (AREA)
Virology (AREA)
Physical Education & Sports Medicine (AREA)
Diabetes (AREA)
Dermatology (AREA)
Cardiology (AREA)
Pulmonology (AREA)
Hematology (AREA)
Tropical Medicine & Parasitology (AREA)
Rheumatology (AREA)
Ophthalmology & Optometry (AREA)
Heart & Thoracic Surgery (AREA)
Biomedical Technology (AREA)
Orthopedic Medicine & Surgery (AREA)
Neurosurgery (AREA)
Neurology (AREA)
Molecular Biology (AREA)
Psychiatry (AREA)
Obesity (AREA)
Hospice & Palliative Care (AREA)
Vascular Medicine (AREA)
Addiction (AREA)

ZA200409388A 2002-05-17 2004-11-22 Methods and compositions using immunodulatory compounds for treatment and management of cancers and other diseases ZA200409388B (en)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
US38084202P	2002-05-17	2002-05-17
US42460002P	2002-11-06	2002-11-06

Publications (1)

Publication Number	Publication Date
ZA200409388B true ZA200409388B (en)	2006-05-31

Family

ID=29553516

Family Applications (3)

Application Number	Title	Priority Date	Filing Date
ZA200503656A ZA200503656B (en)	2002-05-17	2003-11-06	Methods for treatment and management of brain cancer using 1-oxo-2-(2,6-dioxopiperidin-3-yl)-4-methylisoindoline
ZA200409387A ZA200409387B (en)	2002-05-17	2004-11-22	Methods and compositions using selective cytokine inhibitory drugs for treatment and management of cancers and other diseases
ZA200409388A ZA200409388B (en)	2002-05-17	2004-11-22	Methods and compositions using immunodulatory compounds for treatment and management of cancers and other diseases

Family Applications Before (2)

Application Number	Title	Priority Date	Filing Date
ZA200503656A ZA200503656B (en)	2002-05-17	2003-11-06	Methods for treatment and management of brain cancer using 1-oxo-2-(2,6-dioxopiperidin-3-yl)-4-methylisoindoline
ZA200409387A ZA200409387B (en)	2002-05-17	2004-11-22	Methods and compositions using selective cytokine inhibitory drugs for treatment and management of cancers and other diseases

Country Status (19)

Country	Link
EP (9)	EP2105136A3 (xx)
JP (8)	JP2005530784A (xx)
KR (2)	KR100793564B1 (xx)
CN (13)	CN103494817A (xx)
AT (1)	ATE459357T1 (xx)
AU (1)	AU2003234626B2 (xx)
CA (10)	CA2727824A1 (xx)
CY (3)	CY1110013T1 (xx)
DE (1)	DE60331537D1 (xx)
DK (1)	DK1505973T3 (xx)
ES (2)	ES2521672T3 (xx)
IL (9)	IL165254A0 (xx)
LU (1)	LU92642I2 (xx)
MX (1)	MXPA04011311A (xx)
NZ (5)	NZ549175A (xx)
PT (2)	PT2105135E (xx)
SI (1)	SI1505973T1 (xx)
WO (1)	WO2003097052A2 (xx)
ZA (3)	ZA200503656B (xx)

Families Citing this family (69)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
HU228769B1 (en)	1996-07-24	2013-05-28	Celgene Corp	Substituted 2(2,6-dioxopiperidin-3-yl)phthalimides and -1-oxoisoindolines and their use for production of pharmaceutical compositions for mammals to reduce the level of tnf-alpha
EP1389203B8 (en)	2001-02-27	2010-03-10	The Governement of the United States of America, represented by The Secretary Department of Health and Human services	Analogs of thalidomide as angiogenesis inhibitors
CN103494817A (zh)	2002-05-17	2014-01-08	细胞基因公司	用于治疗和控制多发性骨髓瘤的方法及组合物
US7393862B2 (en) *	2002-05-17	2008-07-01	Celgene Corporation	Method using 3-(4-amino-1-oxo-1,3-dihydro-isoindol-2-yl)-piperidine-2,6-dione for treatment of certain leukemias
US7323479B2 (en) *	2002-05-17	2008-01-29	Celgene Corporation	Methods for treatment and management of brain cancer using 1-oxo-2-(2,6-dioxopiperidin-3-yl)-4-methylisoindoline
US7189740B2 (en)	2002-10-15	2007-03-13	Celgene Corporation	Methods of using 3-(4-amino-oxo-1,3-dihydro-isoindol-2-yl)-piperidine-2,6-dione for the treatment and management of myelodysplastic syndromes
US11116782B2 (en)	2002-10-15	2021-09-14	Celgene Corporation	Methods of treating myelodysplastic syndromes with a combination therapy using lenalidomide and azacitidine
US8404716B2 (en)	2002-10-15	2013-03-26	Celgene Corporation	Methods of treating myelodysplastic syndromes with a combination therapy using lenalidomide and azacitidine
EP1562597A4 (en) *	2002-10-31	2008-05-14	Celgene Corp	COMPOSITIONS COMPRISING IMMUNOMODULATORY COMPOUNDS FOR THE TREATMENT AND MANAGEMENT OF MACULAR DEGENERATION AND METHODS OF USE THEREOF
US7785601B2 (en) *	2002-12-31	2010-08-31	Sygnis Bioscience Gmbh & Co. Kg	Methods of treating neurological conditions with hematopoietic growth factors
WO2005016326A2 (en) *	2003-07-11	2005-02-24	The Government Of The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services	Analogs of thalidomide as potential angiogenesis inhibitors
UA83504C2 (xx)	2003-09-04	2008-07-25	Селджин Корпорейшн	Поліморфні форми 3-(4-аміно-1-оксо-1,3-дигідроізоіндол-2-іл)піперидин-2,6-діону$полиморфные формы 3-(4-амино-1-оксо-1,3-дигидроизоиндол-2-ил) пиперидин-2,6-диона
US8952895B2 (en)	2011-06-03	2015-02-10	Apple Inc.	Motion-based device operations
CA2538864C (en)	2003-09-17	2013-05-07	The Government Of The United States Of America, As Represented By The Secretary Of The Department Of Health And Human Services	Thalidomide analogs as tnf-alpha modulators
US20050100529A1 (en) *	2003-11-06	2005-05-12	Zeldis Jerome B.	Methods of using and compositions comprising immunomodulatory compounds for the treatment and management of asbestos-related diseases and disorders
CA2547570A1 (en) *	2003-12-02	2005-06-23	Celgene Corporation	4-(amino)-2-(2,6-dioxo(3-piperidyl))-isoindoline-1,3-dione for induction of fetal hemoglobin in individuals having anemia
US20050143344A1 (en) *	2003-12-30	2005-06-30	Zeldis Jerome B.	Methods and compositions using immunomodulatory compounds for the treatment and management of central nervous system disorders or diseases
CA2601278C (en)	2004-03-17	2014-06-10	Lars Michael Larsen	Prevention of retinopathy by inhibition of the visual cycle
CA2560221C (en) *	2004-03-22	2010-12-07	Celgene Corporation	Methods of using and compositions comprising immunomodulatory compounds for the treatment and management of skin diseases or disorders
CA2562715A1 (en) *	2004-04-14	2005-11-24	Celgene Corporation	Methods of using and compositions comprising immunomodulatory compounds for the treatment and management of myelodysplastic syndromes
KR20070086000A (ko) *	2004-11-12	2007-08-27	셀진 코포레이션	기생충성 질병의 치료 및 관리를 위한 면역조절성 화합물을사용하는 방법 및 조성물
US20060122228A1 (en) *	2004-11-23	2006-06-08	Zeldis Jerome B	Methods and compositions using immunomodulatory compounds for treatment and management of central nervous system injury
CA2621136C (en) *	2005-09-01	2014-10-14	Celgene Corporation	Immunological uses of immunomodulatory compounds for vaccine and anti-infectious disease therapy
WO2007072225A2 (en) *	2005-12-01	2007-06-28	Medical Prognosis Institute	Methods and devices for identifying biomarkers of treatment response and use thereof to predict treatment efficacy
AU2007238785B2 (en)	2006-04-13	2013-02-07	Agnieszka Ambrozak	Tetrahalogenated compounds useful as inhibitors of angiogenesis
RU2426542C2 (ru) *	2006-05-26	2011-08-20	Селджин Корпорейшн	Способы и композиции с применением иммуномодулирующих соединений при комбинированном лечении
CL2007002218A1 (es) *	2006-08-03	2008-03-14	Celgene Corp Soc Organizada Ba	Uso de 3-(4-amino-1-oxo-1,3-dihidro-isoindol-2-il)-piperidina 2,6-diona para la preparacion de un medicamento util para el tratamiento de linfoma de celula de capa.
AU2007281684C1 (en) *	2006-08-07	2013-12-19	Abbvie Biotherapeutics Inc.	Methods of treating multiple myeloma using combination therapies based on anti-CS1 antibodies
US20110184025A1 (en) *	2006-10-19	2011-07-28	Hensel Jennifer L	Methods and Compositions Using Immunomodulatory Compounds for the Treatment and Management of Spirochete and Other Obligate Intracellular Bacterial Diseases
RU2348420C2 (ru) *	2007-04-17	2009-03-10	ФГУ Ростовский научно-исследовательский онкологический институт Росздрава	Способ лечения местно-распространенного рака легкого
KR101955140B1 (ko) *	2007-09-28	2019-03-06	안트로제네시스 코포레이션	인간 태반 관류액 및 인간 태반-유래 중간체 천연 킬러 세포를 사용한 종양 억제 방법
UA104579C2 (uk)	2007-12-10	2014-02-25	Байокрист Фармасьютикалз, Инк.	Спосіб лікування раку кровотворної системи із застосуванням фородезину у комбінації з ритуксимабом
MX2010008220A (es) *	2008-01-29	2010-08-23	Celgene Corp	Metodos que usan compuestos inmunomoduladores para modular nivel de cd59.
RU2398525C1 (ru) *	2009-03-25	2010-09-10	Федеральное государственное учреждение "Ростовский научно-исследовательский онкологический институт Росмедтехнологий"	Способ лечения рака легкого
CN101696205B (zh)	2009-11-02	2011-10-19	南京卡文迪许生物工程技术有限公司	3-(取代二氢异吲哚-2-基)-2,6-哌啶二酮多晶型物和药用组合物
MX2012005849A (es) *	2009-11-24	2012-08-23	Celgene Corp	Compuestos inmunomoduladores para la restauracion de la sensibilidad a vitamina d en celulas tumorales resistentes a vitamina d.
HRP20171078T1 (hr)	2010-02-11	2017-10-06	Celgene Corporation	Derivati arilmetoksi izoindolina i pripravci koji ih sadrže, te postupci njihove uporabe
CN103068386A (zh) *	2010-03-12	2013-04-24	细胞基因公司	使用来那度胺治疗非霍奇金淋巴瘤的方法及作为预测因子的基因和蛋白质生物标记
US10426740B1 (en)	2010-08-18	2019-10-01	Avm Biotechnology, Llc	Compositions and methods to inhibit stem cell and progenitor cell binding to lymphoid tissue and for regenerating germinal centers in lymphatic tissues
CN103167870B (zh) *	2010-08-18	2018-11-16	T·迭舍尔	抑制干细胞和祖细胞与淋巴样组织结合和用于使淋巴组织中的生发中心再生的组合物和方法
WO2012062366A1 (en) *	2010-11-11	2012-05-18	Ingo Schmidt-Wolf	Compositions comprising wnt inhibitors for treating cancer
US8927725B2 (en)	2011-12-02	2015-01-06	The United States Of America, As Represented By The Secretary, Department Of Health And Human Services	Thio compounds
MX2015003114A (es) *	2012-09-10	2015-07-06	Celgene Corp	Metodos para el tratamiento de cancer de mama localmente avanzado.
WO2014165482A1 (en) *	2013-04-02	2014-10-09	Celgene Corporation	Methods and compositions using 4-amino-2-(2,6-dioxo-piperidine-3-yl)-isoindoline-1,3-dione for treatment and management of central nervous system cancers
GB201322626D0 (en)	2013-12-19	2014-02-05	Immutep S A	Combined preparations for the treatment of cancer
CN104231068A (zh) *	2014-01-27	2014-12-24	苏州发士达生物科技有限公司	人白细胞介素ii突变体及其应用
JP6616934B2 (ja) *	2014-05-22	2019-12-04	株式会社資生堂	レナリドミドの光学分割方法
BR112017003620A2 (pt)	2014-08-22	2017-12-05	Celgene Corp	métodos de tratamento de mieloma múltiplo com compostos imunomoduladores em combinação com anticorpos
US10570457B2 (en)	2014-09-26	2020-02-25	Medical Prognosis Institute A/S	Methods for predicting drug responsiveness
GB201500374D0 (en)	2015-01-09	2015-02-25	Immutep S A	Combined preparations for the treatment of cancer
CN107249502A (zh) *	2015-01-20	2017-10-13	斯里瓦特桑·拉加万	自照明式面颊牵开器
CN108366987A (zh)	2015-04-30	2018-08-03	河谷控股Ip有限责任公司	通过致畸药物化合物对患者进行治疗
CN107949425A (zh) *	2015-06-29	2018-04-20	百时美施贵宝公司	用于治疗癌症的包含泊马度胺和抗cs1抗体的免疫治疗给药方案
IL309273A (en) *	2015-10-21	2024-02-01	Teclison Ltd	Compositions and methods for immune-mediated cancer therapy
CN105388237B (zh) *	2015-12-28	2017-02-01	成都百裕金阁莱药业有限公司	阿普斯特中3‑乙酰氨基邻苯二甲酸的检测方法
US9725769B1 (en)	2016-10-07	2017-08-08	Oncology Venture ApS	Methods for predicting drug responsiveness in cancer patients
AU2017258901A1 (en)	2016-12-30	2018-07-19	Allarity Therapeutics Europe ApS	Methods for predicting drug responsiveness in cancer patients
JP2020506922A (ja)	2017-01-31	2020-03-05	アルビナス・オペレーションズ・インコーポレイテッドＡｒｖｉｎａｓＯｐｅｒａｔｉｏｎｓ，Ｉｎｃ．	セレブロンリガンド、およびセレブロンリガンドを含有する二官能性化合物
AU2018243753A1 (en)	2017-04-01	2019-10-10	Avm Biotechnology, Llc	Replacement of cytotoxic preconditioning before cellular immunotherapy
CN110662762A (zh)	2017-05-24	2020-01-07	诺华股份有限公司	抗体细胞因子移植蛋白和用于治疗癌症的方法
US20200323838A1 (en) *	2017-10-26	2020-10-15	Synbias Pharma Ag	Lenalidomide immediate release formulations
MY206796A (en)	2018-04-23	2025-01-08	Celgene Corp	Substituted 4-aminoisoindoline-1,3-dione compounds and their use for treating lymphoma
KR102718800B1 (ko) *	2018-05-23	2024-10-18	셀진 코포레이션	다발성 골수종의 치료 및 4-(4-(4-(((2-(2,6-디옥소피페리딘-3-일)-1-옥소이소인돌린-4-일)옥시)메틸)벤질)피페라진-1-일)-3-플루오로벤조니트릴에 대한 바이오마커의 용도
KR20210056397A (ko) *	2018-09-07	2021-05-18	메드샤인 디스커버리 아이엔씨.	삼환식 치환 피페리딘 디온계 화합물
EP3488851A1 (en)	2018-10-03	2019-05-29	AVM Biotechnology, LLC	Immunoablative therapies
US20240216354A1 (en) *	2019-10-04	2024-07-04	Dana-Farber Cancer Institute, Inc.	Immunomodulatory imide drugs as zeta-chain-associated protein kinase 70 (zap70) agonists and uses thereof
KR20220103949A (ko) *	2019-10-21	2022-07-25	셀진 코포레이션	혈액암을 치료하는 방법 및 2-(2,6-디옥소피페리딘-3-일)-4-((2-플루오로-4-((3-모르폴리노아제티딘-1-일)메틸)벤질)아미노)이소인돌린-1,3-디온에 대한 동반 바이오마커의 용도
HUE064768T2 (hu) *	2019-10-21	2024-04-28	Celgene Corp	Eljárások hematológiai malignitások kezelésére 2-(2,6-dioxopiperidin-3-il)-4-((2-fluor-4-((3-morfolinoazetidin-1-il)metil)benzil)amino)izoindolin-1,3-dion alkalmazásával
CR20220353A (es)	2019-12-19	2022-10-20	Arvinas Operations Inc	Compuestos y métodos para la degradación dirigida del receptor de andrógenos

Family Cites Families (41)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US3228601A (en)	1964-02-20	1966-01-11	Monarch Marking Systems Inc	Controls for marking machine
US3536809A (en)	1969-02-17	1970-10-27	Alza Corp	Medication method
US3598123A (en)	1969-04-01	1971-08-10	Alza Corp	Bandage for administering drugs
US3845770A (en)	1972-06-05	1974-11-05	Alza Corp	Osmatic dispensing device for releasing beneficial agent
US3916899A (en)	1973-04-25	1975-11-04	Alza Corp	Osmotic dispensing device with maximum and minimum sizes for the passageway
US4008719A (en)	1976-02-02	1977-02-22	Alza Corporation	Osmotic system having laminar arrangement for programming delivery of active agent
US4994443A (en)	1982-12-20	1991-02-19	The Children's Medical Center Corporation	Inhibition of angiogenesis
US5001116A (en)	1982-12-20	1991-03-19	The Children's Medical Center Corporation	Inhibition of angiogenesis
IE58110B1 (en)	1984-10-30	1993-07-14	Elan Corp Plc	Controlled release powder and process for its preparation
US5391485A (en)	1985-08-06	1995-02-21	Immunex Corporation	DNAs encoding analog GM-CSF molecules displaying resistance to proteases which cleave at adjacent dibasic residues
JPS63500636A (ja)	1985-08-23	1988-03-10	麒麟麦酒株式会社	多分化能性顆粒球コロニー刺激因子をコードするｄｎａ
US4810643A (en)	1985-08-23	1989-03-07	Kirin- Amgen Inc.	Production of pluripotent granulocyte colony-stimulating factor
US5073543A (en)	1988-07-21	1991-12-17	G. D. Searle & Co.	Controlled release formulations of trophic factors in ganglioside-lipsome vehicle
IT1229203B (it)	1989-03-22	1991-07-25	Bioresearch Spa	Impiego di acido 5 metiltetraidrofolico, di acido 5 formiltetraidrofolico e dei loro sali farmaceuticamente accettabili per la preparazione di composizioni farmaceutiche in forma a rilascio controllato attive nella terapia dei disturbi mentali organici e composizioni farmaceutiche relative.
US5120548A (en)	1989-11-07	1992-06-09	Merck & Co., Inc.	Swelling modulated polymeric drug delivery device
KR0166088B1 (ko)	1990-01-23	1999-01-15	.	수용해도가 증가된 시클로덱스트린 유도체 및 이의 용도
US5733566A (en)	1990-05-15	1998-03-31	Alkermes Controlled Therapeutics Inc. Ii	Controlled release of antiparasitic agents in animals
US5580578A (en)	1992-01-27	1996-12-03	Euro-Celtique, S.A.	Controlled release formulations coated with aqueous dispersions of acrylic polymers
US5360352A (en)	1992-12-24	1994-11-01	The Whitaker Corporation	Wire retainer for current mode coupler
US5591767A (en)	1993-01-25	1997-01-07	Pharmetrix Corporation	Liquid reservoir transdermal patch for the administration of ketorolac
US5629327A (en)	1993-03-01	1997-05-13	Childrens Hospital Medical Center Corp.	Methods and compositions for inhibition of angiogenesis
US6114355A (en)	1993-03-01	2000-09-05	D'amato; Robert	Methods and compositions for inhibition of angiogenesis
US5698579A (en)	1993-07-02	1997-12-16	Celgene Corporation	Cyclic amides
IT1270594B (it)	1994-07-07	1997-05-07	Recordati Chem Pharm	Composizione farmaceutica a rilascio controllato di moguisteina in sospensione liquida
US5798368A (en)	1996-08-22	1998-08-25	Celgene Corporation	Tetrasubstituted 2-(2,6-dioxopiperidin-3-yl)-1-oxoisoindolines and method of reducing TNFα levels
US5635517B1 (en)	1996-07-24	1999-06-29	Celgene Corp	Method of reducing TNFalpha levels with amino substituted 2-(2,6-dioxopiperidin-3-YL)-1-oxo-and 1,3-dioxoisoindolines
US6281230B1 (en) *	1996-07-24	2001-08-28	Celgene Corporation	Isoindolines, method of use, and pharmaceutical compositions
CZ302378B6 (cs)	1996-07-24	2011-04-20	Celgene Corporation	Optický izomer (S)-1,3-dioxo-2-(2,6-dioxopiperidin-3-yl)-4-aminoisoindolin a farmaceutická kompozice s jeho obsahem
HU228769B1 (en)	1996-07-24	2013-05-28	Celgene Corp	Substituted 2(2,6-dioxopiperidin-3-yl)phthalimides and -1-oxoisoindolines and their use for production of pharmaceutical compositions for mammals to reduce the level of tnf-alpha
EP1361210B1 (en)	1996-08-12	2008-12-24	Celgene Corporation	Novel immunotherapeutic agents and their use in the reduction of cytokine levels
EP1586322B1 (en) *	1996-11-05	2008-08-20	The Children's Medical Center Corporation	Compositions comprising thalodimide and dexamethasone for the treatment of cancer& x9;
US5874448A (en)	1997-11-18	1999-02-23	Celgene Corporation	Substituted 2-(2,6 dioxo-3-fluoropiperidin-3-yl)-isoindolines and method of reducing TNFα levels
US6020358A (en) *	1998-10-30	2000-02-01	Celgene Corporation	Substituted phenethylsulfones and method of reducing TNFα levels
DE60042968D1 (de) *	1999-04-01	2009-10-29	Hana Biosciences Inc	Zusammensetzungen und methoden zur behandlung lymphoma
CZ20023330A3 (cs) *	2000-03-17	2003-02-12	Cell Therapeutics, Inc.	Konjugáty kamptotecinu a polyglutamové kyseliny a způsoby přípravy
PT1307197E (pt) *	2000-05-15	2006-08-31	Celgene Corp	Composicoes para o tratamento do cancro compreendendo um inibidor de topoisomerase e talidomida
US6458810B1 (en) *	2000-11-14	2002-10-01	George Muller	Pharmaceutically active isoindoline derivatives
AU2002253795B2 (en)	2000-11-30	2007-02-01	The Children's Medical Center Corporation	Synthesis of 4-Amino-Thalidomide enantiomers
US20030045552A1 (en) *	2000-12-27	2003-03-06	Robarge Michael J.	Isoindole-imide compounds, compositions, and uses thereof
CN103494817A (zh) *	2002-05-17	2014-01-08	细胞基因公司	用于治疗和控制多发性骨髓瘤的方法及组合物
US7323479B2 (en) *	2002-05-17	2008-01-29	Celgene Corporation	Methods for treatment and management of brain cancer using 1-oxo-2-(2,6-dioxopiperidin-3-yl)-4-methylisoindoline

2003
- 2003-05-16 CN CN201310344609.6A patent/CN103494817A/zh not_active Withdrawn
- 2003-05-16 CA CA2727824A patent/CA2727824A1/en not_active Abandoned
- 2003-05-16 PT PT90087560T patent/PT2105135E/pt unknown
- 2003-05-16 NZ NZ549175A patent/NZ549175A/en not_active IP Right Cessation
- 2003-05-16 ES ES09008756.0T patent/ES2521672T3/es not_active Expired - Lifetime
- 2003-05-16 ES ES03728969T patent/ES2340027T3/es not_active Expired - Lifetime
- 2003-05-16 CA CA2752127A patent/CA2752127A1/en not_active Abandoned
- 2003-05-16 DE DE60331537T patent/DE60331537D1/de not_active Expired - Lifetime
- 2003-05-16 CN CN038168995A patent/CN1697655B/zh not_active Expired - Lifetime
- 2003-05-16 AU AU2003234626A patent/AU2003234626B2/en not_active Expired
- 2003-05-16 JP JP2004505051A patent/JP2005530784A/ja active Pending
- 2003-05-16 CN CN2011102571780A patent/CN102429908A/zh active Pending
- 2003-05-16 NZ NZ584663A patent/NZ584663A/en not_active IP Right Cessation
- 2003-05-16 DK DK03728969.1T patent/DK1505973T3/da active
- 2003-05-16 NZ NZ572388A patent/NZ572388A/en not_active IP Right Cessation
- 2003-05-16 SI SI200331793T patent/SI1505973T1/sl unknown
- 2003-05-16 WO PCT/US2003/015470 patent/WO2003097052A2/en not_active Ceased
- 2003-05-16 CA CA2794060A patent/CA2794060C/en not_active Expired - Lifetime
- 2003-05-16 EP EP09008775A patent/EP2105136A3/en not_active Withdrawn
- 2003-05-16 PT PT03728969T patent/PT1505973E/pt unknown
- 2003-05-16 CA CA2752140A patent/CA2752140A1/en not_active Abandoned
- 2003-05-16 CA CA2727830A patent/CA2727830C/en not_active Expired - Lifetime
- 2003-05-16 CN CN201110256752.0A patent/CN102379874B/zh not_active Expired - Lifetime
- 2003-05-16 EP EP10185504A patent/EP2316455A1/en not_active Withdrawn
- 2003-05-16 KR KR1020047018587A patent/KR100793564B1/ko not_active Expired - Lifetime
- 2003-05-16 CN CN201310344594.3A patent/CN103393681B/zh not_active Expired - Lifetime
- 2003-05-16 MX MXPA04011311A patent/MXPA04011311A/es active IP Right Grant
- 2003-05-16 EP EP10177041A patent/EP2272512A1/en not_active Withdrawn
- 2003-05-16 KR KR1020067020849A patent/KR100822149B1/ko not_active Expired - Fee Related
- 2003-05-16 CN CN2013103449770A patent/CN103393695A/zh not_active Withdrawn
- 2003-05-16 CN CN2011102566053A patent/CN102302494A/zh active Pending
- 2003-05-16 CN CN201310343756.1A patent/CN103495169B/zh not_active Expired - Lifetime
- 2003-05-16 CN CN2006101504843A patent/CN1981761B/zh not_active Expired - Fee Related
- 2003-05-16 NZ NZ563281A patent/NZ563281A/en not_active IP Right Cessation
- 2003-05-16 CA CA2672000A patent/CA2672000C/en not_active Expired - Lifetime
- 2003-05-16 EP EP09008756.0A patent/EP2105135B1/en not_active Revoked
- 2003-05-16 AT AT03728969T patent/ATE459357T1/de active
- 2003-05-16 CA CA2752124A patent/CA2752124A1/en not_active Abandoned
- 2003-05-16 CA CA2794297A patent/CA2794297A1/en not_active Abandoned
- 2003-05-16 CA CA2752122A patent/CA2752122A1/en not_active Abandoned
- 2003-05-16 EP EP03728969A patent/EP1505973B1/en not_active Revoked
- 2003-05-16 CA CA2476983A patent/CA2476983C/en not_active Expired - Lifetime
- 2003-05-16 CN CN201110257161.5A patent/CN102342938B/zh not_active Expired - Lifetime
- 2003-05-16 EP EP14189022.8A patent/EP2915533B1/en not_active Revoked
- 2003-05-16 EP EP12158938.6A patent/EP2561874A3/en not_active Withdrawn
- 2003-05-16 CN CN2011102561581A patent/CN102335173A/zh active Pending
- 2003-05-16 EP EP10177056A patent/EP2272513A1/en not_active Withdrawn
- 2003-05-16 CN CN201410690665.XA patent/CN104606193A/zh not_active Withdrawn
- 2003-05-16 NZ NZ536907A patent/NZ536907A/en not_active IP Right Cessation
- 2003-05-16 EP EP09004756A patent/EP2087891A3/en not_active Withdrawn
- 2003-05-16 IL IL16525403A patent/IL165254A0/xx unknown
- 2003-11-06 CN CNA2003801083980A patent/CN1735415A/zh active Pending
- 2003-11-06 ZA ZA200503656A patent/ZA200503656B/xx unknown
2004
- 2004-11-16 IL IL165254A patent/IL165254A/en active IP Right Grant
- 2004-11-22 ZA ZA200409387A patent/ZA200409387B/en unknown
- 2004-11-22 ZA ZA200409388A patent/ZA200409388B/xx unknown
2006
- 2006-10-19 IL IL178745A patent/IL178745A/en active Protection Beyond IP Right Term
- 2006-10-19 IL IL178746A patent/IL178746A0/en unknown
- 2006-10-19 IL IL178748A patent/IL178748A/en active IP Right Grant
- 2006-10-19 IL IL178747A patent/IL178747A/en active IP Right Grant
- 2006-10-24 JP JP2006288966A patent/JP2007008966A/ja active Pending
2009
- 2009-05-13 JP JP2009116363A patent/JP2009191072A/ja not_active Withdrawn
- 2009-05-13 JP JP2009116367A patent/JP5839770B2/ja not_active Expired - Lifetime
- 2009-05-26 IL IL198978A patent/IL198978A/en active IP Right Grant
2010
- 2010-04-23 CY CY20101100363T patent/CY1110013T1/el unknown
2012
- 2012-05-10 IL IL219732A patent/IL219732A0/en unknown
- 2012-12-14 JP JP2012273326A patent/JP5830005B2/ja not_active Expired - Lifetime
2013
- 2013-02-28 JP JP2013038222A patent/JP2013126999A/ja not_active Withdrawn
2014
- 2014-11-27 CY CY20141100987T patent/CY1115782T1/el unknown
2015
- 2015-01-27 LU LU92642C patent/LU92642I2/xx unknown
- 2015-02-06 CY CY2015003C patent/CY2015003I1/el unknown
- 2015-06-23 JP JP2015125342A patent/JP6194335B2/ja not_active Expired - Lifetime
2016
- 2016-03-22 IL IL244727A patent/IL244727A0/en unknown
2017
- 2017-05-12 JP JP2017095838A patent/JP2017132817A/ja active Pending

Also Published As

Publication number	Publication date
WO2003097052A3 (en)	2003-12-18
EP2087891A2 (en)	2009-08-12
CN1697655B (zh)	2013-09-18
KR20060110014A (ko)	2006-10-23
DK1505973T3 (da)	2010-05-31
DE60331537D1 (de)	2010-04-15
IL198978A (en)	2011-08-31
CN1735415A (zh)	2006-02-15
CN103393681A (zh)	2013-11-20
JP2013049734A (ja)	2013-03-14
JP2013126999A (ja)	2013-06-27
MXPA04011311A (es)	2005-02-14
CA2794060C (en)	2017-08-22
EP2272513A1 (en)	2011-01-12
AU2003234626B2 (en)	2006-03-09
CA2476983A1 (en)	2003-11-27
CN104606193A (zh)	2015-05-13
CA2672000A1 (en)	2003-11-27
CN103495169B (zh)	2016-06-22
CN102379874B (zh)	2016-08-17
CA2752127A1 (en)	2003-11-27
AU2003234626A1 (en)	2003-12-02
EP2105136A3 (en)	2010-01-27
NZ536907A (en)	2006-10-27
CN102379874A (zh)	2012-03-21
CA2794297A1 (en)	2003-11-27
CN102335173A (zh)	2012-02-01
CN1981761A (zh)	2007-06-20
EP2915533B1 (en)	2017-09-13
NZ549175A (en)	2007-12-21
CA2752140A1 (en)	2003-11-27
CA2752122A1 (en)	2003-11-27
CN103393695A (zh)	2013-11-20
IL178745A0 (en)	2007-02-11
CN103494817A (zh)	2014-01-08
CA2727824A1 (en)	2003-11-27
CY1115782T1 (el)	2015-12-09
IL219732A0 (en)	2012-06-28
PT1505973E (pt)	2010-05-21
EP2105135A3 (en)	2010-02-10
IL178747A0 (en)	2007-02-11
NZ584663A (en)	2011-09-30
KR100822149B1 (ko)	2008-04-15
PT2105135E (pt)	2015-02-06
CN103393681B (zh)	2017-04-12
IL178745A (en)	2012-06-28
EP2915533A1 (en)	2015-09-09
JP5830005B2 (ja)	2015-12-09
EP2561874A2 (en)	2013-02-27
EP1505973A2 (en)	2005-02-16
IL178748A0 (en)	2007-02-11
CN103495169A (zh)	2014-01-08
HK1072180A1 (en)	2005-08-19
EP2105135B1 (en)	2014-10-22
ES2521672T3 (es)	2014-11-13
CA2727830C (en)	2014-09-16
CA2476983C (en)	2011-01-25
CY2015003I2 (el)	2015-12-09
EP2272512A1 (en)	2011-01-12
IL165254A (en)	2013-03-24
IL178746A0 (en)	2007-02-11
SI1505973T1 (sl)	2010-06-30
NZ563281A (en)	2009-05-31
EP2105136A2 (en)	2009-09-30
ZA200503656B (en)	2009-02-25
CN1981761B (zh)	2011-10-12
EP2316455A1 (en)	2011-05-04
EP2561874A3 (en)	2013-09-04
CA2794060A1 (en)	2003-11-27
CN102342938B (zh)	2014-08-20
JP2007008966A (ja)	2007-01-18
IL244727A0 (en)	2016-05-01
CN102342938A (zh)	2012-02-08
CN102429908A (zh)	2012-05-02
IL165254A0 (en)	2005-12-18
JP2009173683A (ja)	2009-08-06
NZ572388A (en)	2010-05-28
WO2003097052A2 (en)	2003-11-27
IL178748A (en)	2013-10-31
KR20050010815A (ko)	2005-01-28
ATE459357T1 (de)	2010-03-15
CY1110013T1 (el)	2015-01-14
JP6194335B2 (ja)	2017-09-06
CN102302494A (zh)	2012-01-04
CY2015003I1 (el)	2015-12-09
CA2727830A1 (en)	2003-11-27
CN1697655A (zh)	2005-11-16
ES2340027T3 (es)	2010-05-28
JP2017132817A (ja)	2017-08-03
AU2003234626C1 (en)	2003-12-02
EP2087891A3 (en)	2010-01-27
JP2009191072A (ja)	2009-08-27
ZA200409387B (en)	2006-06-28
EP1505973A4 (en)	2006-05-17
EP1505973B1 (en)	2010-03-03
KR100793564B1 (ko)	2008-01-14
HK1104968A1 (en)	2008-02-01
EP2105135A2 (en)	2009-09-30
JP2015187156A (ja)	2015-10-29
HK1134019A1 (en)	2010-04-16
IL178747A (en)	2015-06-30
CA2672000C (en)	2011-11-29
JP2005530784A (ja)	2005-10-13
JP5839770B2 (ja)	2016-01-06
CA2752124A1 (en)	2003-11-27
LU92642I2 (fr)	2015-04-24

Publication	Publication Date	Title
ZA200409388B (en)	2006-05-31	Methods and compositions using immunodulatory compounds for treatment and management of cancers and other diseases
TW200500355A (en)	2005-01-01	Methods and compositions using immunomodulatory compounds for treatment and management of cancers and other diseases
MXPA05012155A (es)	2006-02-22	Metodos y composiciones que utilizan compuestos inmunomoduladores para el tratamiento y manejo de canceres y otras enfermedades.
WO2005046593A3 (en)	2006-03-02	Methods and compositions using thalidomide for the treatment and management of cancers and other diseases.
TW200501945A (en)	2005-01-16	Methods and compositions using selective cytokine inhibitory drugs for treatment and management of cancers and other diseases
MX2007005570A (es)	2007-07-09	Metodos y composiciones que usan compuestos inmunomoduladores para el tratamiento y manejo de padecimientos parasiticos.
WO2005046318A3 (en)	2007-06-21	Methods of using and compositions comprising immunomodulatory compounds for the treatment and management of asbestos-related diseases and disorders
MXPA05007857A (es)	2005-10-18	Moduladores derivados de indol de receptores nucleares de hormonas esteroideas.
WO2005002582A3 (en)	2005-05-26	Trp-p8 active compounds and therapeutic treatment methods
IL164564A0 (en)	2005-12-18	Combination therapy for the treatment of cancer
BRPI0418801A (pt)	2007-10-16	métodos de tratamento, controle ou prevenção de um cáncer especìfico, e de uma doença associada com angiogênese indesejada, de redução ou prevenção de um efeito adverso, composição farmacêutica, e, kit
MXPA05006378A (es)	2006-02-08	Compuestos esteroides con actividad anti-tumoral.
MXPA06002939A (es)	2006-05-31	6-aril-7-haloimidazo[1,2-a]pirimidinas como agentes contra el cancer.
YU43302A (sh)	2005-03-15	Supstituisani bisindolilmaleimidi za inhibiciju proliferacije ćelija
AU2003209899A1 (en)	2003-10-08	Dithiolopyrrolone derivatives useful in the treatment of proliferative diseases
TW200519078A (en)	2005-06-16	2-alkylidene-19-nor-vitamin d derivatives for the treatment of a second hip fracture